U.S. FDA extends review of Humacyte blood vessel implant
Humacyte U.S. health regulator said it has expanded the company’s authority to test an implant that can replace a damaged or injured blood vessel, causing its shares to fall more than 15% after the close of trading.
ПОПУЛЯРНЫЕ ПОСТЫ
Putin may discuss Ukraine peace deal with Trump
Ноябрь 22, 2024
Spain’s vice-president Ribera blames floods on climate change
Ноябрь 22, 2024
Storm lashes northwestern US, killing two people
Ноябрь 22, 2024
Iceland volcano erupts for tenth time in three years
Ноябрь 22, 2024
ПОДПИСЫВАЙТЕСЬ НА НАС
ПРЯМАЯ ТРАНСЛЯЦИЯ